Discrepancies among three commercially available luteinising hormone (LH) radioimmunoassay RIA kits, all calibrated against the second-IRP-HMG (World Health Organisation International Laboratory for Biological Standards), were observed.
In laboratory science and clinical chemistry there are no doubts about the importance of internal and external quality control (IQC, EQC) for maintaining high standards in the laboratory.
There is now a need for primary quality control (PQC) both nationally and internationally; it is important for ensuring the accuracy of results. PQC means including the tests run by the manufacturers before they market their product to ensure quality and post-marketing checks to make sure the quality is maintained (fig 1) .' Although every company operates its own PQC system it is our experience that there are often imperfections and the products do not always come up to scratch.
In 1982 and 1983 Shishiba et al reported variations in the results obtained with insulin RIA kits, arising from the standards used, and showed that the technical skill of the user was not a major factor; the inaccurate results reflected the differences in the reference standards.2 They emphasised the importance of establishing international standards which have since been adopted.
In 1986 the Japan Radioisotope Association (JRA) carried out its eighth quality control survey on luteinising hormone RIA kits. This survey showed that there was a large variation between the Daiichi RIA kit (Daiichi RI Co., Tokyo, Japan) which showed a spuriously high result and the EIKEN (EIKEN ICL.
Co., Tokyo, Japan) and Amerlex (Amersham, UK) kits. The mean (SDs) were as follows: 89 5 (6 5); 66-0 (3-9); and 60-1 (4-1) IU/l, respectively (p < 0-001) (fig 1) . The luteinising hormone reference standard of these three kits was calibrated against that of the second Blood RT
